Latest / Eyewire News: The Podcast

Biocon Launches Eylea Biosimilar Yesafili
An interchangeable biosimilar to Eylea is launched in the US; patient enrollment is completed in two global phase 3 clinical trials evaluating Duravyu for diabetic macular edema; and Topcon receives CE mark for a fully automated ultra-widefield retinal slit scanner.
Learn more about your ad choices. Visit megaphone.fm/adchoices
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.